4 Healthcare Stock Stories For Midweek Investment Wellness

GlaxoSmithKline (NYSE:GSK): Closing price $52.00

On Wednesday, GlaxoSmithKline said that it has purchased the specialist developer of vaccine platform technologies, Okairos, for roughly £215 million in a cash transaction. Okairos, a private company based in Switzerland, has created a novel vaccine platform tech which should play an important part in GSK’s development of new prophylactic vaccines (designed to prevent infection), alongside new classes of therapeutic vaccines that are designed to treat infection or disease. Okairos’ tech complements GSK’s existing vaccine technology and expertise, and will permit the latter to continue its work creating the next generation of vaccines.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK

Cyberonics (NASDAQ:CYBX): Closing price $46.85

Cyberonics reported on Wednesday that it received a letter from the Centers of Medicare and Medicaid Services that turned down the firm’s request to reconsider the 2007 National Coverage Determination for the treatment-resistant depression indication. The firm plans to work with other interested parties so as to continue to pursue access to that important therapeutic option for patients who might well benefit from VNS Therapy, including carefully evaluating all options for appealing this decision.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CYBX

Achillion Pharmaceuticals (NASDAQ:ACHN): Closing price $7.44

Achillion announced Wednesday that its President and Chief Executive Michael D. Kishbauch has elected to retire. In response, the board has named President of Research and Development and Chief Scientific Officer, Milind Deshpande, Ph.D., to Kishbauch’s position and to the board. Kishbauch who will continue working with management over a three-month transition period, and he will remain a director on the board.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACHN

Edwards Lifesciences Corporation (NYSE:EW): Closing price $64.26

The corporation said on Wednesday that it has received a warning letter from the Denver District Office of the FDA, resulting from an inspection of Edwards’ facility in Draper, Utah, which concluded in February. The warning relates specifically to the execution of the firm’s quality systems within the Cardiac Surgery Systems division, among which include design and process validation, corrective and preventive actions, finished device acceptance and packaging. However, the firm does not expect that this matter will have a material impact on its 2013 financial guidance.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

EW

Don’t Miss: Will Obamacare’s Insurance Exchanges Be a Bust?

More Articles About:    

More from The Cheat Sheet